Why the study?
The 2015 International Task Force Consensus Statement proposed a risk stratification algorithm for ICD placement in arrhythmogenic right ventricular dysplasia/cardiomyopathy, but its performance required evaluation.
Does the 2015 International Task Force Consensus Statement risk stratification algorithm accurately predict ventricular arrhythmia risk in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy?
Cohort (n=365)
Does the 2015 International Task Force Consensus Statement risk stratification algorithm accurately predict ventricular arrhythmia risk in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy?
The 2015 International Task Force Consensus Statement algorithm for ICD placement in ARVD/C underestimates VT/VF incidence and fails to distinguish VF/flutter risks between Class I and IIa indications, suggesting a need for refinement.
Answers are grounded in this paper and cite their sources.
May underestimate VT/VF risk in ARVD/C; leaves open need for refined, prospectively validated stratification.
Background: Ventricular arrhythmias are a feared complication of arrhythmogenic right ventricular dysplasia/cardiomyopathy. In 2015, an International Task Force Consensus Statement proposed a risk stratification algorithm for implantable cardioverter-defibrillator placement in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Methods and Results: To evaluate performance of the algorithm, 365 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients were classified as having a Class I, IIa, IIb, or III indication per the algorithm at baseline. Survival free from sustained ventricular arrhythmia (VT/VF) in follow-up was the primary outcome. Incidence of ventricular fibrillation/flutter cycle length <240 ms was also assessed. Two hundred twenty-four (61%) patients had a Class I implantable cardioverter-defibrillator indication; 80 (22%), Class IIa; 54 (15%), Class IIb; and 7 (2%), Class III. During a median 4.2 (interquartile range, 1.7–8.4)-year follow-up, 190 (52%) patients had VT/VF and 60 (16%) had ventricular fibrillation/flutter. Although the algorithm appropriately differentiated risk of VT/VF, incidence of VT/VF was underestimated (observed versus expected: 29.6 [95% confidence interval, 25.2–34.0] versus >10%/year Class I; 15.5 [confidence interval 11.1–21.6] versus 1% to 10%/year Class IIa). In addition, the algorithm did not differentiate survival free from ventricular fibrillation/flutter between Class I and IIa patients ( P =0.97) or for VT/VF in Class I and IIa primary prevention patients ( P =0.22). Adding Holter results (<1000 premature ventricular contractions/24 hours) to International Task Force Consensus classification differentiated risks. Conclusions: While the algorithm differentiates arrhythmic risk well overall, it did not distinguish ventricular fibrillation/flutter risks of patients with Class I and IIa implantable cardioverter-defibrillator indications. Limited differentiation was seen for primary prevention cases. As these are vital uncertainties in clinical decision-making, refinements to the algorithm are suggested prior to implementation.
No takes yet. Share an insight, caveat, or question.
Orgeron et al. (2018) conducted a cohort in arrhythmogenic right ventricular dysplasia/cardiomyopathy (n=365). 2015 International Task Force Consensus Statement Risk Stratification Algorithm vs. Algorithm classes (e.g., Class I vs Class IIa) was evaluated on Survival free from sustained ventricular arrhythmia (VT/VF) (p=0.22). The 2015 International Task Force algorithm underestimated VT/VF incidence and did not differentiate VT/VF risk between Class I and IIa primary prevention patients.
Synapse has enriched 10 related papers. Consider them for comparative context: